Wei Lin, M.D. has served as our Chief Medical Officer since April 2023.
Wei brings extensive clinical development expertise to Revolution Medicines. His vast clinical research experience is reflected in numerous publications in esteemed peer-reviewed journals such as The New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology.
Prior to joining us, Wei served as the Chief Medical Officer at Erasca, Inc., a biotechnology company, from January 2021 until April 2023 and as Head of Development at Nektar Therapeutics, a pharmaceutical company, from October 2018 until January 2021. Prior to Nektar, Wei served as the Global Development Leader for cancer immunotherapy in lung and neck cancer at Genentech, Inc., a biotechnology company. He also served as a faculty member at the M.D. Anderson Cancer Center, where he completed his medical oncology fellowship, from 2006 to 2009. Wei is a member of the board of directors of 2seventy bio, Inc. (Nasdaq: TSVT), a biotechnology company.
Wei received a B.A. from Haverford College and an M.D. from Harvard Medical School. He completed his residency in internal medicine at the Massachusetts General Hospital and his fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center.
What is Lin Wei's net worth?
The estimated net worth of Lin Wei is at least $6.93 million as of September 16th, 2025. Dr. Wei owns 88,339 shares of Revolution Medicines stock worth more than $6,932,845 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Wei may own. Learn More about Lin Wei's net worth.
How do I contact Lin Wei?
Has Lin Wei been buying or selling shares of Revolution Medicines?
Lin Wei has not been actively trading shares of Revolution Medicines during the past quarter. Most recently, Lin Wei sold 2,160 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $45.82, for a transaction totalling $98,971.20. Following the completion of the sale, the insider now directly owns 88,339 shares of the company's stock, valued at $4,047,692.98. Learn More on Lin Wei's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), Barbara Weber (Director), and Lin Wei (Chief Medical Officer). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 353,371 shares worth more than $18,977,695.36. The most recent insider tranaction occured on November, 25th when insider Mark A Goldsmith sold 60,000 shares worth more than $4,504,800.00. Insiders at Revolution Medicines own 8.2% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 11/25/2025.
